ANSWER: B

Rationale:

Option B is correct. Angiotensin-converting enzyme (ACE) is a dipeptidyl carboxypeptidase that serves two distinct substrate functions: it cleaves angiotensin I (a decapeptide) to generate angiotensin II (an octapeptide), and it degrades bradykinin (a vasodilatory kinin) into inactive fragments. ACE inhibitors competitively inhibit this enzyme, producing two simultaneous effects: (1) reduced angiotensin II generation, which decreases vasoconstriction, aldosterone release, sympathetic activation, and maladaptive cardiac remodeling; and (2) impaired bradykinin degradation, which raises bradykinin levels and amplifies vasodilation, natriuresis, and endothelial nitric oxide release. Both mechanisms contribute to the hemodynamic and cardioprotective profile of ACEi in HFrEF. The bradykinin accumulation is also responsible for the class-specific adverse effect of dry cough, which occurs in 15–20% of patients.

• Option A: Option A is incorrect; ACE inhibitors do not block the AT1 receptor — that is the mechanism of ARBs (angiotensin receptor blockers); ACEi act upstream at the converting enzyme, not at the receptor level.
• Option C: Option C is incorrect; ACE inhibitors do not suppress renin release by direct juxtaglomerular feedback — in fact, reduced angiotensin II feedback causes a compensatory rise in renin (reactive hyperreninemia); ACEi also have no direct mineralocorticoid receptor antagonist activity.
• Option D: Option D is incorrect; neprilysin inhibition is the mechanism of sacubitril (the neprilysin inhibitor component of sacubitril/valsartan), not of ACE inhibitors; ACEi do not inhibit neprilysin.
• Option E: Option E is incorrect; while angiotensin II does potentiate sympathetic activity through presynaptic receptors, ACEi do not act through direct blockade of presynaptic adrenergic receptors; the sympatholytic effect of ACEi is indirect, mediated by reduced angiotensin II levels rather than direct receptor blockade at nerve terminals.

ANSWER: D

Rationale:

Option D is correct. The CONSENSUS trial (1987) was the first randomized controlled trial to demonstrate that an ACE inhibitor reduced all-cause mortality in heart failure. It enrolled 253 patients with severe symptomatic HF (NYHA class III–IV) and randomized them to enalapril or placebo added to conventional therapy (diuretics and digoxin). Enalapril reduced all-cause mortality by 27% at 6 months and 40% at 1 year, with the greatest benefit in reducing death from progressive heart failure. The trial was stopped early by the safety monitoring committee due to the magnitude of survival benefit. CONSENSUS established the proof of concept that neurohormonal blockade — specifically RAAS inhibition — could modify the natural history of HFrEF and reduce mortality, not merely improve symptoms.

• Option A: Option A is incorrect; the SOLVD-Treatment trial enrolled patients with LVEF ≤35% who were largely NYHA class II–III (mildly to moderately symptomatic), not asymptomatic or NYHA class I; it demonstrated a 16% reduction in all-cause mortality with enalapril, but CONSENSUS preceded it and focused on the more severe NYHA III–IV population.
• Option B: Option B is incorrect; the ATLAS trial compared high-dose to low-dose lisinopril and found a trend toward reduced mortality with high-dose therapy that did not reach statistical significance for all-cause mortality; its primary contribution was to support titration to higher doses for morbidity reduction, not to establish the initial mortality benefit of ACEi in HF.
• Option C: Option C is incorrect; Val-HeFT demonstrated a reduction in HF hospitalization with valsartan added to conventional therapy but did not demonstrate a significant reduction in all-cause mortality; furthermore, the combination of ACEi plus ARB is no longer recommended due to adverse renal and hemodynamic outcomes demonstrated in ONTARGET.
• Option E: Option E is incorrect; the CHARM-Alternative trial established candesartan as an effective alternative in ACEi-intolerant patients but did not study all-cause mortality as a primary endpoint in isolation, and ARBs are not the preferred first-line agent — sacubitril/valsartan is now the preferred RAAS-blocking strategy in eligible HFrEF patients.

ANSWER: A

Rationale:

Option A is correct. ACE inhibitor-induced cough is a well-characterized class effect with an incidence of approximately 15–20% in Western populations and higher rates (up to 30–40%) in East Asian populations. The mechanism is bradykinin accumulation: ACE (angiotensin-converting enzyme) is the primary enzyme responsible for degrading bradykinin in the pulmonary vasculature and bronchial mucosa. When ACE is inhibited, bradykinin accumulates and stimulates bradykinin B2 receptors on bronchial sensory C-fiber afferents, lowering the cough reflex threshold and producing a persistent dry cough. Substance P, also degraded by ACE, may contribute to a lesser degree. Critically, this is a class effect — it occurs with all ACE inhibitors regardless of dose, does not improve with dose reduction, and resolves only upon discontinuation of the ACEi. Switching to an ARB (which does not inhibit ACE and therefore does not raise bradykinin) reliably resolves the cough.

• Option B: Option B is incorrect; ACEi-induced cough is not mediated through AT2 receptor suppression or AT1-driven bronchoconstriction — the mechanism is bradykinin accumulation, not receptor imbalance; the cough is not partially reversible with inhaled corticosteroids.
• Option C: Option C is incorrect; ACE inhibitors do not upregulate substance P degradation — they impair it, since ACE also degrades substance P; the mechanism described involving neutral endopeptidase disinhibition and mast cell histamine release is pharmacologically fabricated.
• Option D: Option D is incorrect; angiotensin I accumulation is not the cause of ACEi cough; angiotensin I does not directly activate bronchial TRP channels in this manner; the cough is not dose-dependent and cannot be attenuated by dose reduction — this is a fundamental clinical distinction that drives the decision to switch drug class rather than adjust dose.
• Option E: Option E is incorrect; while bradykinin does stimulate prostaglandin synthesis, the mechanism of ACEi cough is neurogenic (C-fiber sensitization), not impaired mucociliary clearance from reduced prostaglandin E2; this description conflates downstream bradykinin signaling pathways with the primary cough mechanism.

ANSWER: E

Rationale:

Option E is correct. ARBs (angiotensin receptor blockers) act by selectively blocking the AT1 receptor, preventing angiotensin II from binding to its primary effector receptor. Critically, ARBs do not inhibit angiotensin-converting enzyme (ACE) — the enzyme responsible for both generating angiotensin II from angiotensin I and degrading bradykinin. Because ACE remains fully active in patients on ARBs, bradykinin is metabolized at its normal rate and does not accumulate in the bronchial mucosa. Since ACEi-induced cough is caused specifically by bradykinin accumulation sensitizing bronchial C-fiber afferents, and ARBs do not raise bradykinin, cough is not a class effect of ARBs. The incidence of cough with ARBs is comparable to placebo. This mechanistic distinction is clinically important: patients who develop ACEi cough can be switched to an ARB (or directly to sacubitril/valsartan) with reliable resolution of cough. The option also correctly notes that angioedema risk, while substantially reduced compared to ACEi, is not entirely eliminated with ARBs — a separate angioedema mechanism exists involving angiotensin II itself at the AT2 receptor. Option D is correct in its mechanistic core (ACE continues to function, bradykinin does not accumulate) but is incomplete — it omits the key mechanistic contrast (receptor-level vs. enzyme-level action) that explains why ARBs lack this effect, and the option wording implies this is a limitation rather than a clinically important distinction; option E provides the complete and accurate explanation.

• Option A: Option A is incorrect; ARBs do not inhibit neprilysin — neprilysin inhibition is the mechanism of sacubitril; ARBs do not reduce bradykinin below baseline levels; the description of a shifted degradation pathway is pharmacologically fabricated.
• Option B: Option B is incorrect; while ARBs do allow unopposed angiotensin II to accumulate and bind AT2 receptors (a potentially favorable effect), AT2 receptor activation does not suppress bronchial bradykinin B2 receptor expression; the absence of cough with ARBs is explained by intact ACE activity and normal bradykinin degradation, not AT2-mediated receptor suppression.
• Option C: Option C is incorrect; ARBs are not ACE inhibitors and do not bind to ACE at any site — allosteric or otherwise; ARBs act exclusively at the angiotensin II receptor level, not at the converting enzyme.

ANSWER: C

Rationale:

Option C is correct. Neprilysin (also called neutral endopeptidase or enkephalinase) is a membrane-bound zinc metallopeptidase that degrades a broad range of vasoactive peptides. Its most therapeutically relevant substrates in HFrEF are the natriuretic peptides: ANP (atrial natriuretic peptide, released in response to atrial stretch), BNP (B-type natriuretic peptide, released in response to ventricular wall stress), and CNP (C-type natriuretic peptide, with local vascular and renal effects). These peptides exert counter-regulatory effects that directly oppose the maladaptive neurohormonal activation of HFrEF: they promote natriuresis and diuresis, produce systemic and pulmonary vasodilation, inhibit renin and aldosterone release, suppress sympathetic nervous system activity, and inhibit cardiac fibrosis and pathological hypertrophy. In HFrEF, natriuretic peptide signaling is overwhelmed by the severity of neurohormonal activation; inhibiting their degradation via neprilysin inhibition amplifies their endogenous counter-regulatory function. This is the mechanistic basis for sacubitril's therapeutic benefit — and the reason it must be combined with valsartan (AT1 blockade), since neprilysin also degrades angiotensin II and its inhibition would otherwise raise Ang II levels dangerously.

• Option A: Option A is incorrect; neprilysin does not convert angiotensin I to angiotensin II — that is the function of ACE (angiotensin-converting enzyme); while neprilysin does degrade angiotensin II (among many substrates), its inhibition raises rather than reduces Ang II, which is why the valsartan component is required.
• Option B: Option B is incorrect; while neprilysin does degrade endothelin-1, the therapeutic mechanism of sacubitril is not ET-B receptor-mediated vasodilation; ET-B receptor stimulation on vascular endothelium does produce nitric oxide release, but this is not the primary or established mechanism of benefit; the central mechanism is natriuretic peptide accumulation.
• Option D: Option D is incorrect; neprilysin inhibition does not suppress pro-BNP to BNP conversion — pro-BNP is cleaved to BNP by furin and corin, not by neprilysin; neprilysin degrades the already-active BNP peptide; the consequence of neprilysin inhibition is increased circulating BNP, not decreased BNP, which is a clinically important biomarker implication.
• Option E: Option E is incorrect; while neprilysin does degrade bradykinin and sacubitril does raise bradykinin levels, bradykinin elevation is not the primary mechanism of therapeutic benefit in HFrEF — it is a secondary effect that may contribute modestly to vasodilation; the established and primary mechanism is natriuretic peptide accumulation and amplification of counter-regulatory signaling.

ANSWER: B

Rationale:

Option B is correct. BNP (B-type natriuretic peptide) is a peptide hormone released primarily from ventricular cardiomyocytes in response to increased wall stress and volume overload. It is a substrate for neprilysin — the same enzyme inhibited by the sacubitril component of sacubitril/valsartan. When neprilysin is inhibited, BNP degradation in the circulation is impaired, causing BNP levels to rise independent of any change in true ventricular wall stress or filling pressures. This creates an artifactual elevation of BNP that does not reflect worsening HF. Conversely — and more dangerously — it means that a BNP value that appears "normal" or "acceptable" in a patient on sacubitril/valsartan may actually represent a true elevation that has been masked by uncertainty about the degree of neprilysin inhibition's contribution. NT-proBNP (N-terminal pro-BNP) is the inactive cleavage fragment of the BNP prohormone; it is not a neprilysin substrate and its clearance is not affected by sacubitril; NT-proBNP therefore remains a reliable marker of HF severity and congestion in patients receiving sacubitril/valsartan and should always be used in preference to BNP in this population.

• Option A: Option A is incorrect; while sacubitril/valsartan does reduce neurohormonal activation and may modestly reduce BNP synthesis over time, the primary reason BNP is unreliable in this setting is impaired degradation from neprilysin inhibition, not genuine normalization of wall stress; accepting a BNP of 180 pg/mL as reassuringly low in a symptomatic patient on sacubitril/valsartan would be a clinically dangerous interpretation.
• Option C: Option C is incorrect; there is no structural homology between valsartan and BNP that causes assay interference; BNP immunoassays use antibodies directed against the BNP ring structure and are not subject to competitive inhibition by valsartan or any ARB.
• Option D: Option D is incorrect; sacubitril/valsartan does not upregulate NPR-A expression through a RAAS-independent genomic mechanism that accelerates receptor-mediated clearance; this mechanism is pharmacologically fabricated; receptor-mediated clearance of natriuretic peptides occurs through NPR-C (the clearance receptor), and sacubitril does not upregulate NPR-C in a manner that would produce falsely low BNP.
• Option E: Option E is incorrect; RAAS blockade through ACEi or ARB alone does not impair BNP measurement; the biomarker unreliability is specific to neprilysin inhibition by sacubitril, which directly prevents BNP degradation; NT-proBNP is not a neprilysin substrate and remains reliable in patients on ACEi, ARB, or ARNI therapy.

ANSWER: D

Rationale:

Option D is correct. PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) enrolled 8,442 patients with chronic HFrEF (LVEF ≤40%, NYHA class II–IV, elevated natriuretic peptides) and randomized them to sacubitril/valsartan 200 mg (97/103 mg) twice daily or enalapril 10 mg twice daily. The primary endpoint — composite of cardiovascular death or first HF hospitalization — was reduced by 20% (HR 0.80; 95% CI 0.73–0.87; p<0.001). Secondary endpoints of all-cause mortality (16% reduction), cardiovascular mortality (20% reduction), HF hospitalization (21% reduction), and sudden cardiac death (20% reduction) were all significantly improved. The trial was stopped early by the data safety monitoring board for overwhelming efficacy. A key design feature was the mandatory sequential run-in period: all enrolled patients first received enalapril alone, then sacubitril/valsartan alone, before randomization — selecting a population that had demonstrated tolerability of both agents and therefore likely underestimates the absolute benefit in unselected real-world patients. The NNT (number needed to treat) to prevent one cardiovascular death or HF hospitalization over 27 months was approximately 21.

• Option A: Option A is incorrect; PARADIGM-HF did not compare sacubitril/valsartan to placebo on background ACEi — it compared sacubitril/valsartan directly to enalapril (an ACEi) as the active comparator; combining an ARNI with an ACEi is contraindicated, and this design would be inappropriate.
• Option B: Option B is incorrect; PARADIGM-HF was a randomized clinical outcomes trial, not a pharmacokinetic bridging or dose-equivalence study; it measured cardiovascular death and HF hospitalization as primary endpoints, not plasma angiotensin II suppression.
• Option C: Option C is incorrect in a subtle but important way — this option is nearly identical to D but omits the phrase "before randomization" from the run-in period description; the run-in's clinical significance lies specifically in pre-randomization tolerability selection, and its omission creates an incomplete and potentially misleading characterization of trial design.
• Option E: Option E is incorrect; PARADIGM-HF demonstrated statistically significant reductions in cardiovascular mortality as an independent endpoint (not only as part of the composite); there is no black-box warning on sacubitril/valsartan suggesting mortality benefit was driven entirely by hospitalization reduction — this characterization is a fabrication.

ANSWER: A

Rationale:

Option A is correct. Before initiating sacubitril/valsartan in a patient currently receiving an ACE inhibitor, a mandatory 36-hour washout period after the last ACEi dose is required. The pharmacological rationale is the risk of life-threatening angioedema from combined bradykinin accumulation. ACE inhibitors prevent bradykinin degradation by inhibiting angiotensin-converting enzyme, which is one of the primary enzymes responsible for bradykinin inactivation. Neprilysin — inhibited by the sacubitril component of sacubitril/valsartan — is a second, independent enzyme that also degrades bradykinin. If both enzymes are simultaneously inhibited (ACEi + sacubitril), bradykinin accumulates to levels far exceeding those produced by either agent alone, raising the risk of angioedema — including potentially fatal laryngeal angioedema — to an unacceptable level. The 36-hour washout allows ACEi levels to fall sufficiently to restore partial ACE activity before neprilysin inhibition is layered on. This requirement is absolute and applies regardless of the ACEi dose or the patient's prior tolerability of the ACEi. When transitioning from an ARB to sacubitril/valsartan, no washout is required because ARBs do not inhibit ACE and do not raise bradykinin.

• Option B: Option B is incorrect; no gradual taper of the ACEi is required or recommended before transitioning to sacubitril/valsartan; the transition protocol requires cessation of the ACEi followed by a 36-hour washout, not dose tapering; the concern driving the washout is angioedema risk, not rebound neurohormonal activation.
• Option C: Option C is incorrect; concurrent use of an ACEi and sacubitril/valsartan is contraindicated — not complementary — because it produces dangerous bradykinin accumulation; dual RAAS coverage with ACEi plus ARNI is not guideline-endorsed at any transition stage.
• Option D: Option D is incorrect; valsartan does not displace ACEi molecules from the ACE active site — valsartan acts at the AT1 receptor, not at ACE; there is no pharmacodynamic displacement mechanism that eliminates the bradykinin risk within 2–4 hours of stopping an ACEi.
• Option E: Option E is incorrect; lisinopril does not have a half-life of less than 4 hours — it has a prolonged effective half-life of approximately 12 hours for the parent compound, with tissue ACE inhibition persisting for substantially longer; the 36-hour washout is empirically established based on pharmacodynamic recovery of ACE activity, not simple pharmacokinetic clearance.

ANSWER: C

Rationale:

Option C is correct. The combination of an ACE inhibitor and an ARB — representing dual RAAS blockade at two levels (enzyme and receptor) — was investigated on the premise that more complete angiotensin II suppression would produce additive cardiovascular benefit. The CHARM-Added trial did demonstrate that candesartan added to background ACEi reduced the composite of cardiovascular death and HF hospitalization, driven primarily by a reduction in HF hospitalization. However, the ONTARGET trial (which enrolled a broader population of high-cardiovascular-risk patients) demonstrated that combining ramipril with telmisartan produced significantly increased rates of hypotension, acute kidney injury, doubling of serum creatinine, and initiation of dialysis compared to either agent alone, without any reduction in the primary composite of cardiovascular death, MI, stroke, or HF hospitalization. The renal harm without survival benefit shifted the risk-benefit calculus decisively against this combination. Current 2022 AHA/ACC/HFSA guidelines do not recommend routine ACEi plus ARB dual therapy in HFrEF. The combination is additionally and specifically contraindicated when an MRA (mineralocorticoid receptor antagonist such as spironolactone or eplerenone) is already part of the regimen — the triple combination (ACEi + ARB + MRA) produces unacceptable rates of hyperkalemia and renal deterioration. Option B is correct in substance and largely overlaps with option C, but is less complete — it omits the specific contraindication of the ACEi + ARB combination in the presence of a concomitant MRA, which is a distinct and clinically important additional prohibition; option C is the more complete and therefore preferred answer.

• Option A: Option A is incorrect; the 2022 AHA/ACC/HFSA guidelines do not endorse dual ACEi plus ARB therapy as a Class IIa recommendation; the recommendation in symptomatic patients who need more complete RAAS blockade is to transition to sacubitril/valsartan, not to add an ARB to an ACEi; CHARM-Added reduced hospitalizations but did not produce an all-cause mortality reduction that would support a Class IIa survival-modifying recommendation.
• Option D: Option D is incorrect; dual ACEi plus ARB therapy is not endorsed as a transitional strategy when switching to sacubitril/valsartan; the correct transition protocol requires cessation of the ACEi followed by a 36-hour washout before starting sacubitril/valsartan, not concurrent overlap of ACEi and ARB components.
• Option E: Option E is incorrect; the contraindication to dual ACEi plus ARB therapy is not limited to hyperkalemia risk; the ONTARGET data showed renal harm as the predominant adverse signal; the combination is not recommended even in patients with normal potassium and preserved renal function, as these parameters can deteriorate rapidly with dual RAAS blockade. --- SECTION 2: CONCEPT CONNECTORS ---

ANSWER: E

Rationale:

Option E is correct. Neprilysin is a promiscuous peptidase with many vasoactive substrates. While its therapeutically targeted substrates are the natriuretic peptides (ANP, BNP, CNP), neprilysin also degrades angiotensin II, endothelin-1, bradykinin, substance P, and adrenomedullin, among others. When neprilysin is inhibited by sacubitril, the degradation of angiotensin II is also impaired, causing Ang II levels to rise. Ang II is the primary driver of maladaptive neurohormonal activation in HFrEF — producing vasoconstriction, aldosterone secretion, sympathetic activation, and pathological cardiac fibrosis and hypertrophy. A standalone neprilysin inhibitor would therefore produce a pharmacodynamically contradictory effect: simultaneously raising counter-regulatory natriuretic peptides and raising the maladaptive signaling molecule Ang II. The clinical precursor to sacubitril/valsartan, a dual ACE inhibitor-neprilysin inhibitor called omapatrilat, confirmed this problem by producing dangerous angioedema from combined bradykinin accumulation. The sacubitril/valsartan design resolves this by pairing neprilysin inhibition with AT1 receptor blockade through valsartan — preventing Ang II from acting on its primary effector receptor while preserving the natriuretic peptide amplification benefit of neprilysin inhibition.

• Option A: Option A is incorrect; natriuretic peptides do not suppress sinoatrial node automaticity to a clinically significant degree at physiological or pharmacologically elevated concentrations; bradycardia is not a recognized adverse effect of neprilysin inhibition, and valsartan is not included to attenuate NPR-A signaling.
• Option B: Option B is incorrect; the necessity of the combination is pharmacodynamic, not pharmacokinetic; sacubitril bioavailability is not limited by P-glycoprotein efflux, and valsartan does not function as a P-glycoprotein inhibitor to enhance sacubitril absorption; the formulation rationale is entirely mechanistic.
• Option C: Option C is incorrect; natriuretic peptide receptor downregulation from excessive NPR-A stimulation is not an established mechanism of clinical significance with sacubitril therapy; there is no evidence that NPR-A internalization is driven by AT1 receptor signaling in a manner that valsartan would prevent; this mechanism is pharmacologically fabricated.
• Option D: Option D is incorrect; neprilysin does not degrade aldosterone in the adrenal cortex in a clinically meaningful pathway; aldosterone excess is not a consequence of neprilysin inhibition; the rationale for including valsartan is Ang II accumulation at the systemic level, not adrenal aldosterone synthesis.

ANSWER: B

Rationale:

Option B is correct. The transition rules for RAAS-modifying agents in HFrEF are mechanistically driven and differ depending on the direction and agents involved. For Patient 1 (ACEi → sacubitril/valsartan): a mandatory 36-hour washout after the last ACEi dose is required. The rationale is angioedema prevention — ACE inhibitors raise bradykinin by blocking ACE-mediated bradykinin degradation; neprilysin inhibition (sacubitril) raises bradykinin by blocking neprilysin-mediated bradykinin degradation; concurrent inhibition of both pathways produces additive bradykinin accumulation far exceeding either agent alone, with unacceptable angioedema risk. For Patient 2 (ARB → sacubitril/valsartan): no washout is required. ARBs block the AT1 receptor but do not inhibit ACE; bradykinin degradation proceeds normally on ARB therapy; there is no bradykinin accumulation risk to carry over into sacubitril/valsartan initiation; discontinue the ARB on the day sacubitril/valsartan is started. For Patient 3 (sacubitril/valsartan → ACEi): a 36-hour washout after stopping sacubitril/valsartan is required before initiating the ACEi, for the same mechanistic reason applied in reverse — residual neprilysin inhibition from sacubitril combined with new ACEi-mediated bradykinin accumulation produces the same dangerous interaction.

• Option A: Option A is incorrect; Patient 2 does not require a 36-hour washout — the rationale for the ACEi washout is bradykinin accumulation from dual enzyme inhibition, which does not apply to ARB-to-ARNI transitions; additionally, Patient 3 does require a 36-hour washout before starting the ACEi, which this option incorrectly dismisses.
• Option C: Option C is incorrect; a 24-hour washout is not sufficient for ramipril — ramiprilat (the active diacid metabolite) has a prolonged effective half-life and tissue ACE inhibition persists well beyond plasma clearance; the 36-hour washout is established based on pharmacodynamic recovery of ACE activity, not plasma half-life of the parent compound.
• Option D: Option D is incorrect; a universal 36-hour washout for all RAAS transitions is not guideline-endorsed; the ARB-to-ARNI transition specifically requires no washout, and applying one unnecessarily delays therapy initiation without any mechanistic justification.
• Option E: Option E is incorrect; Patient 2 does not require a 72-hour washout — there is no pharmacodynamic basis for prolonged AT1 receptor occupancy from standalone valsartan potentiating hypotension from the valsartan component of sacubitril/valsartan; and Patient 3 requires a 36-hour washout, not 48 hours, per established transition protocols.

ANSWER: D

Rationale:

Option D is correct. PIONEER-HF (Comparison of Sacubitril/Valsartan versus Enalapril on Effect on NT-proBNP in Patients Stabilized from an Acute Heart Failure Episode) was a randomized, double-blind trial that specifically addressed in-hospital ARNI initiation. It enrolled 881 patients who had been hospitalized for acute decompensated HFrEF (LVEF ≤40%) and had achieved hemodynamic stabilization (defined as SBP ≥100 mmHg, no IV vasodilators or positive inotropes for at least 6 hours, no IV diuretics for at least 6 hours, and adequate volume status). Patients were randomized to sacubitril/valsartan or enalapril in-hospital, prior to discharge. The primary endpoint — time-averaged proportional change in NT-proBNP from baseline to weeks 4 and 8 — showed a significantly greater NT-proBNP reduction with sacubitril/valsartan (46.7% vs. 25.3%; ratio of change 0.71, 95% CI 0.63–0.81). Crucially, there was no significant difference in rates of worsening renal function, hyperkalemia, symptomatic hypotension, or angioedema between the two arms, establishing that in-hospital initiation is safe when patients meet hemodynamic stabilization criteria. PIONEER-HF provided the prospective evidence base for in-hospital ARNI initiation currently reflected in guidelines.

• Option A: Option A is incorrect; PARADIGM-HF did not include a pre-specified subgroup of patients enrolled within 72 hours of hospitalization for acute decompensated HF; PARADIGM-HF enrolled outpatients with chronic stable HFrEF; it was specifically PIONEER-HF that addressed the in-hospital initiation question prospectively.
• Option B: Option B is incorrect; STRONG-HF examined high-intensity GDMT optimization strategy in recently hospitalized patients but did not compare sacubitril/valsartan directly to enalapril, and it did not demonstrate a 42% reduction in in-hospital mortality; STRONG-HF's contribution was establishing rapid post-discharge GDMT uptitration with close follow-up as superior to usual care.
• Option C: Option C is incorrect; no trial called ATMOSPHERE demonstrated that in-hospital ARNI initiation was terminated for safety due to renal harm; this trial description is fabricated; PIONEER-HF reached the opposite conclusion — in-hospital initiation was safe.
• Option E: Option E is incorrect; PIONEER-HF is a prospective randomized trial that directly examined in-hospital initiation; the statement that no such trial exists is factually wrong; guideline support for in-hospital ARNI initiation rests on prospective evidence, not solely on post-hoc analyses and registry data.

ANSWER: A

Rationale:

Option A is correct. RAAS blockade with ACEi or sacubitril/valsartan is appropriate and guideline-indicated in patients with HFrEF and moderate CKD (eGFR approximately 20–60 mL/min/1.73m²). The cardioprotective mortality benefit of RAAS blockade in HFrEF extends to patients with reduced eGFR; withholding survival-modifying therapy based on moderate CKD alone would deny patients a meaningful mortality benefit without adequate justification. A modest creatinine rise — up to approximately 30% above baseline — after RAAS blocker initiation is expected and represents a hemodynamic effect (reduced intraglomerular hydraulic pressure from efferent arteriolar dilation) rather than intrinsic nephrotoxicity. This degree of creatinine elevation does not predict accelerated CKD progression and is not an indication to discontinue therapy. The correct approach is to initiate at the lowest available dose, monitor potassium and creatinine at 1–2 weeks after initiation and after each dose increase, and continue therapy unless renal function deteriorates beyond acceptable thresholds or significant hyperkalemia (K⁺ >5.5 mEq/L) develops. Sacubitril/valsartan is not specifically contraindicated in moderate CKD; pharmacokinetic adjustments are not required until eGFR falls below approximately 25–30 mL/min/1.73m². Option E is correct in its specific content about avoiding RAAS initiation during AKI and using sick day rules, but it addresses a narrower subset of the clinical question — when to withhold rather than when to initiate; option A provides the more complete evidence-based framework for the management of HFrEF with stable moderate CKD.

• Option B: Option B is incorrect; there is no eGFR threshold of 45 mL/min/1.73m² that constitutes a contraindication to RAAS blockade in HFrEF; hydralazine/isosorbide dinitrate is specifically recommended in self-identified Black patients with persistent NYHA III–IV symptoms despite optimized therapy, not as a RAAS-sparing substitute for patients with moderate CKD in any racial group.
• Option C: Option C is incorrect; sacubitril/valsartan is not contraindicated at eGFR below 60 mL/min/1.73m²; it can be used with eGFR as low as 25–30 mL/min/1.73m² with dose adjustment; the assertion that sacubitril/valsartan causes additive nephrotoxicity through natriuretic peptide excess is pharmacologically unsupported.
• Option D: Option D is incorrect; the 2022 AHA/ACC/HFSA guidelines do not require nephrology consultation before initiating RAAS blockade in HFrEF patients with CKD stage 3; internists, hospitalists, and cardiologists initiate these drugs routinely in moderate CKD without specialist clearance; nephrology referral may be appropriate in advanced or rapidly progressive CKD but is not a guideline-mandated prerequisite.

ANSWER: C

Rationale:

Option C is correct. The 2022 AHA/ACC/HFSA guidelines give H/ISDN (hydralazine/isosorbide dinitrate) a Class I recommendation as additive therapy in patients of self-identified Black race with HFrEF who remain symptomatic (NYHA class III–IV) despite optimized ACEi or ARB therapy plus a beta-blocker. The evidence basis is the A-HeFT trial (African American Heart Failure Trial), which randomized 1,050 self-identified Black patients with NYHA class III–IV HFrEF to fixed-dose H/ISDN combination (BiDil) or placebo added to standard HF therapy (which included ACEi or ARB in the majority of patients). The trial was stopped early for overwhelming efficacy: H/ISDN reduced all-cause mortality by 43% and HF hospitalization by 33%. The critical clinical principle is that H/ISDN is additive to RAAS blockade — it is not a substitute for ACEi, ARB, or ARNI. There is no trial evidence demonstrating that H/ISDN replaces the mortality benefit of RAAS blockade in any population. In the described patient already on sacubitril/valsartan, the addition of H/ISDN represents the correct application of this recommendation. Option B is largely correct in its content but slightly overstates the mortality reduction —

• Option A: Option A is incorrect; H/ISDN is not recommended as a RAAS-replacing first-line therapy in any population including Black patients; the rationale for its use is additive neurohormonal modulation through nitric oxide-mediated pathways in a population where A-HeFT demonstrated specific benefit; while Black patients on average have lower renin levels, this does not contraindicate RAAS blockade and is not the basis for H/ISDN use.
• Option C: option C states 43% accurately — and the key clinical framing in option B (additive, not replacement) is correct; however option C is the more complete and precisely worded answer that directly addresses the guideline classification and clinical scenario.
• Option D: Option D is incorrect; H/ISDN is not a Class IIb recommendation — it carries a Class I indication in the specified population; H/ISDN in A-HeFT was an additive strategy, not a substitution strategy for patients who developed RAAS blocker adverse effects; characterizing it as a replacement for RAAS blockers is a guideline misrepresentation.
• Option E: Option E is incorrect; A-HeFT did not restrict enrollment to patients with eGFR >60 mL/min/1.73m²; the current guideline recommendation does not include an eGFR-based restriction; patients with moderate CKD who meet other criteria are eligible for H/ISDN addition per the guideline indication.

ANSWER: E

Rationale:

Option E is correct. Hypotension is the most common adverse effect of sacubitril/valsartan requiring dose adjustment, occurring in approximately 18% of patients in PARADIGM-HF. However, asymptomatic hypotension — particularly blood pressure in the range of 80–90 mmHg in a patient with advanced HFrEF who is clinically well-perfused — is a common finding in patients on optimized GDMT and does not automatically mandate discontinuation of survival-modifying therapy. The initial management approach prioritizes identifying and correcting reversible causes. Diuretic-induced volume depletion is the most common correctable cause: reducing or temporarily holding furosemide reduces preload-dependence and often raises blood pressure adequately. Reviewing the timing of ARNI dosing (e.g., separating peak effect times of different agents) and assessing other vasodilators that are not survival-modifying (e.g., nitrates, alpha-blockers) are additional steps. Patients with advanced HFrEF often tolerate SBP of 80–90 mmHg without symptoms of tissue hypoperfusion; the clinical test is whether the patient is symptomatic (dizziness, presyncope, fatigue, reduced urine output), not whether an arbitrary numerical threshold is met. Only if these maneuvers fail and the patient remains symptomatic or hemodynamically compromised should sacubitril/valsartan dose reduction or temporary hold be considered. Option D is largely correct in its approach — reduce furosemide, ensure euvolemia, do not automatically remove RAAS therapy — but is less complete than option E in addressing the full management framework including dosing timing adjustment and the clinical principle of tolerating asymptomatic low BP in advanced HFrEF.

• Option A: Option A is incorrect; asymptomatic blood pressure below 90 mmHg is not an absolute contraindication to continued sacubitril/valsartan per the 2022 AHA/ACC/HFSA guidelines; there is no black-box warning on sacubitril/valsartan mandating discontinuation at any specific asymptomatic BP threshold; immediate discontinuation and downgrading to ACEi is not the appropriate first response to asymptomatic hypotension.
• Option B: Option B is incorrect; dose reduction of sacubitril/valsartan may ultimately be appropriate if simpler maneuvers fail, but it is not the first-line intervention for asymptomatic hypotension; additionally, dismissing beta-blocker contribution to hypotension is incorrect — carvedilol has significant alpha-1 and beta-blocking vasodilatory activity that contributes to blood pressure lowering.
• Option C: Option C is incorrect; carvedilol should not be immediately discontinued as a first response; while beta-blockers can contribute to hypotension, they are survival-modifying in HFrEF and should not be the first agent removed; diuretic dose adjustment is a more appropriate initial intervention for suspected volume depletion-related asymptomatic hypotension.

ANSWER: B

Rationale:

Option B is correct. The SOLVD-Treatment trial (Studies of Left Ventricular Dysfunction, Treatment arm) enrolled 2,569 patients with symptomatic HFrEF (LVEF ≤35%, predominantly NYHA class II–III) and randomized them to enalapril or placebo added to background diuretic and digoxin therapy. Enalapril reduced all-cause mortality by 16% (RR 0.84; 95% CI 0.74–0.95; p=0.0036) over a mean follow-up of 41.4 months. The combined endpoint of death or HF hospitalization was reduced by 26%. Taken together with CONSENSUS (which demonstrated benefit in NYHA III–IV severe HF), SOLVD-Treatment established that the mortality benefit of ACE inhibition spans the full symptomatic spectrum of HFrEF — from the milder end (NYHA class II) through severe disease (NYHA class IV). This evidence base supports the guideline recommendation for ACEi (or preferably ARNI) in all symptomatic HFrEF patients (LVEF ≤40%) regardless of symptomatic severity, provided no contraindication exists. Option D is partially correct in its description of V-HeFT II — which did compare enalapril to hydralazine/ISDN and showed enalapril superiority for mortality — but V-HeFT II enrolled primarily NYHA class II–III patients and compared two active vasodilator strategies, not enalapril versus placebo; it cannot be cited as providing the first placebo-controlled mortality evidence for ACEi in mild-to-moderate HFrEF.

• Option A: Option A is incorrect; CHARM-Alternative enrolled ACEi-intolerant patients and established candesartan as an effective alternative in that population; while candesartan reduced the composite of cardiovascular death and HF hospitalization, it is the ARB evidence for ACEi-intolerant patients, not the trial that extended mortality evidence to mild-to-moderate HFrEF in ACEi-tolerant patients — which was SOLVD-Treatment.
• Option C: Option C is incorrect; ATLAS compared high-dose to low-dose lisinopril and did not include a placebo arm; it therefore cannot establish mortality benefit of ACEi over no treatment; ATLAS demonstrated a trend toward reduced all-cause mortality with high-dose lisinopril that did not reach statistical significance, and a significant reduction in the combined endpoint of death or hospitalization.
• Option E: Option E is incorrect; MERIT-HF was a beta-blocker trial (metoprolol succinate versus placebo) in HFrEF, not an ACEi trial; perindopril was not the study drug; the statement that beta-blockers add no incremental benefit over optimized ACEi is the opposite of what MERIT-HF demonstrated. --- SECTION 3: BRIDGE QUESTIONS ---

ANSWER: D

Rationale:

Option D is correct. This question integrates three connected principles from CHF-02: (1) BNP is a neprilysin substrate — sacubitril inhibits neprilysin, impairing BNP degradation and causing BNP to accumulate artifactually in the circulation, independent of true ventricular wall stress or filling pressures; (2) NT-proBNP is not a neprilysin substrate and is therefore the appropriate biomarker for assessing HF severity and congestion in patients receiving sacubitril/valsartan; (3) clinical assessment cannot be replaced by biomarker results alone — a patient with 4 kg of weight gain and worsening dyspnea over 2 weeks has clear clinical signals of probable volume overload that warrant direct evaluation of volume status (jugular venous pressure, peripheral edema, pulmonary auscultation, orthopnea history) and measurement of NT-proBNP to guide diuretic management. Accepting a BNP of 210 pg/mL as reassuringly low in this clinical context — without accounting for the pharmacological reason it is uninterpretable — is the key error the intern makes. Option D correctly identifies the biomarker error, names the correct substitute (NT-proBNP), and integrates the clinical picture rather than dismissing it. Option C is correct in its pharmacological reasoning and clinical guidance but is slightly less complete than option D — it does not explicitly address why the intern's interpretation is dangerous (i.e., that the weight gain/dyspnea cannot be dismissed on the basis of an uninterpretable BNP) and does not integrate the clinical picture as directly; option D provides the more complete clinical integration.

• Option A: Option A is incorrect; the BNP result is uninterpretable on sacubitril/valsartan — it cannot be used to conclude that neurohormonal activation is adequately suppressed; attributing 4 kg weight gain and dyspnea to non-cardiac causes without first establishing a reliable HF biomarker assessment and direct volume status evaluation is clinically inappropriate.
• Option B: Option B is incorrect on two counts: BNP is not a reliable biomarker in patients on sacubitril/valsartan (the intern's core error), and empirically doubling the furosemide dose without confirmed volume overload on a valid assessment risks overdiuresis, which can worsen renal function and hemodynamics in HFrEF.
• Option E: Option E is incorrect; there is no validated BNP correction factor of 3.2 (or any other factor) established in PARADIGM-HF or any other trial for converting BNP values in patients on neprilysin inhibitors to an "equivalent unmedicated" BNP level; such a correction factor has not been validated for clinical use, and applying one would be pharmacologically inappropriate.

ANSWER: A

Rationale:

Option A is correct. A history of ACE inhibitor-associated angioedema is an absolute contraindication to sacubitril/valsartan. The mechanistic basis for this contraindication is important: sacubitril inhibits neprilysin, which is an independent bradykinin-degrading enzyme; in a patient whose bradykinin metabolism is already sensitized by prior ACEi angioedema, adding neprilysin inhibition raises bradykinin through a second enzymatic pathway and represents unacceptable angioedema risk, including potentially fatal laryngeal angioedema. Sacubitril/valsartan is therefore absolutely contraindicated in patients with any history of ACEi-associated or ARNI-associated angioedema, regardless of the interval since the prior episode. The correct RAAS-blocking strategy in this patient is an ARB. ARBs block the AT1 receptor without inhibiting ACE or neprilysin, and therefore do not raise bradykinin. The risk of angioedema with ARBs is substantially lower than with ACEi (ARB angioedema is mediated by Ang II at AT2 receptors rather than bradykinin and is far less common), and ARBs are the guideline-endorsed RAAS-blocking alternative for patients who cannot receive ACEi or ARNI. Valsartan and candesartan both have HFrEF outcome evidence.

• Option B: Option B is incorrect; ARBs are not contraindicated in patients with prior ACEi angioedema; the mechanism of ACEi angioedema (bradykinin accumulation from ACE inhibition) is distinct from ARB-related angioedema (Ang II-mediated AT2 receptor mechanism); there is no meaningful pharmacological cross-reactivity; ARBs are safe and guideline-endorsed in this clinical context.
• Option C: Option C is incorrect; ACEi-associated angioedema history is an absolute contraindication to sacubitril/valsartan regardless of the relative degree of bradykinin accumulation compared to ACEi; there is no role for a test-dose challenge in clinic in a patient with a history of severe angioedema requiring intubation; the risk of fatal laryngeal angioedema makes this approach clinically unacceptable.
• Option D: Option D is incorrect; while the statement correctly distinguishes ACE inhibition from neprilysin inhibition as distinct bradykinin-raising pathways, the clinical conclusion is wrong; the prior angioedema history from ACEi is an absolute contraindication to sacubitril/valsartan precisely because neprilysin inhibition provides a second independent route for bradykinin elevation; mechanistic distinction does not negate the contraindication.
• Option E: Option E is incorrect; a 30-day ARB trial to establish tolerance before attempting sacubitril/valsartan is not an endorsed or safe pathway in a patient with prior severe ACEi angioedema; even if the ARB is tolerated, sacubitril/valsartan remains absolutely contraindicated due to the bradykinin-raising effect of neprilysin inhibition; there is no validated tolerance-window protocol that overrides this contraindication.

ANSWER: C

Rationale:

Option C is correct. The ATLAS trial enrolled 3,164 patients with HFrEF (LVEF ≤30%, NYHA class II–IV) and compared high-dose lisinopril (32.5–35 mg daily) to low-dose lisinopril (2.5–5 mg daily). The primary endpoint of all-cause mortality showed a non-significant 8% reduction favoring high-dose therapy (p=0.128). However, the combined endpoint of death or hospitalization for any cause was significantly reduced by 12% (p=0.002), and HF hospitalization specifically was reduced by 24% with high-dose therapy. The trial established that while the mortality benefit of dose titration did not reach statistical significance as an isolated endpoint, the morbidity burden — particularly HF hospitalizations, which drive enormous quality-of-life impairment and healthcare utilization — is significantly reduced at higher doses. This provides the evidence base for the guideline recommendation to titrate ACEi to the highest tolerated dose in HFrEF patients. Clinically, a patient feeling well at low dose does not mean their risk of HF hospitalization or disease progression is optimized — it means the current dose is tolerated and that uptitration should proceed as planned.

• Option A: Option A is incorrect; the pharmacological premise that low doses of lisinopril achieve insufficient tissue ACE inhibition is not accurate — even low doses of most ACEi produce substantial tissue ACE inhibition; the rationale for titration is not incomplete enzyme inhibition at low doses but rather the dose-response relationship for morbidity outcomes demonstrated in ATLAS.
• Option B: Option B is incorrect; SOLVD-Treatment was not designed as a dose-response trial — it compared enalapril to placebo at a single fixed-dose range; SOLVD-Treatment did not demonstrate a dose-response relationship for mortality reduction; the ATLAS trial is the evidence source for dose-response in ACEi therapy in HFrEF.
• Option D: Option D is incorrect; ACEi act through non-competitive (irreversible or slowly reversible) inhibition of ACE, not competitive displacement at the active site; the concept of higher plasma ACEi concentrations overcoming competitive displacement by angiotensin I is mechanistically incorrect for most ACEi at therapeutic doses.
• Option E: Option E is incorrect; the 2022 AHA/ACC/HFSA guidelines do not require 6 months of maximum-dose ACEi therapy before transitioning to sacubitril/valsartan; the guideline recommendation is to transition ACEi-tolerant patients to sacubitril/valsartan when feasible, following the 36-hour washout protocol; there is no mandated duration of prior ACEi therapy before ARNI eligibility.

ANSWER: E

Rationale:

Option E is correct. Hyperkalemia is a recognized and predictable adverse effect of RAAS blockade in HFrEF, resulting from reduced aldosterone-mediated urinary potassium excretion. The combination of RAAS blockade (sacubitril/valsartan) and MRA (spironolactone) produces additive potassium-elevating effects. A potassium of 5.6 mEq/L represents mild hyperkalemia in an asymptomatic patient at his baseline creatinine — it does not require acute cardiac protection interventions (calcium gluconate, insulin-dextrose) at this level in an asymptomatic individual, and it does not mandate immediate discontinuation of survival-modifying agents. The initial management framework is: (1) dietary counseling — reduce high-potassium foods (bananas, oranges, tomatoes, potatoes) and stop potassium supplements or salt substitutes containing KCl; (2) identify the most modifiable contributor — spironolactone, acting directly on the mineralocorticoid receptor in the cortical collecting duct to reduce potassium excretion, is often the most targeted dose-reduction candidate when tolerated; (3) repeat monitoring at 1–2 weeks to assess response; (4) escalate to dose reduction or temporary hold of RAAS therapy only if K⁺ rises above 6.0 mEq/L or symptoms develop. The intern's reflex to stop both sacubitril/valsartan and spironolactone simultaneously, at K⁺ of 5.6 mEq/L, is an overreaction that would leave the patient without two Class I survival-modifying therapies for a manageable electrolyte abnormality. Option C is largely correct in its management approach and would be a reasonable answer, but it is slightly less complete than option E in explaining the mechanistic reason that spironolactone is often the first agent to adjust (direct tubular potassium retention via aldosterone receptor blockade) and in addressing the full initial management framework including potassium supplement and salt substitute review. Option D is correct in recommending spironolactone dose reduction and dietary counseling, but incorrectly states that ARNI-related hyperkalemia is mediated exclusively through the valsartan component; the combined RAAS and natriuretic peptide effects both contribute; the statement that no further sacubitril/valsartan adjustment is necessary unless K⁺ exceeds 6.0 mEq/L is reasonable but the mechanistic framing is inaccurate.

• Option A: Option A is incorrect; stopping sacubitril/valsartan as the first step for mild hyperkalemia is not the appropriate initial response; spironolactone dose reduction, not ARNI discontinuation, is the more logical first adjustment; additionally, natriuretic peptide-mediated potassium effects from sacubitril are minor compared to direct RAAS blockade.
• Option B: Option B is incorrect; IV calcium gluconate and insulin-dextrose are acute cardiac protection measures indicated for severe hyperkalemia (K⁺ typically >6.5 mEq/L) with ECG changes or symptomatic patients; these interventions are not indicated for a K⁺ of 5.6 mEq/L in an asymptomatic patient; permanent discontinuation of both agents and replacement with H/ISDN is a disproportionate and guideline-inconsistent response to mild hyperkalemia.

ANSWER: B

Rationale:

Option B is correct. The standard monitoring schedule for renal function and electrolytes following RAAS blocker initiation (ACEi, ARB, or ARNI) in HFrEF is: (1) 1–2 weeks after initiation; (2) 1–2 weeks after each dose increase during titration; (3) 3 months after reaching the target dose; (4) at least every 6 months during stable maintenance therapy. This schedule is designed to detect the two most common and clinically significant adverse effects of RAAS blockade — hyperkalemia and creatinine elevation — at the time points when they are most likely to manifest: shortly after a pharmacodynamic change (new initiation or dose increase) and at regular intervals during maintenance. The sick day rule component is equally important clinically: volume depletion from any cause (gastroenteritis, febrile illness, excessive heat exposure, excessive diuresis) reduces renal perfusion and dramatically increases the risk of AKI when RAAS blockers are continued; temporary hold during such episodes is a guideline-endorsed safety practice that prevents avoidable acute kidney injury.

• Option A: Option A is incorrect; checking labs at 24–48 hours after each dose change is excessive and not the guideline-recommended interval; the maximal hemodynamic renal effect of RAAS blockade typically manifests over days to 1–2 weeks, not 24–48 hours; the recommended post-change monitoring interval is 1–2 weeks, which allows clinically meaningful changes to become apparent without subjecting patients to unnecessarily frequent phlebotomy.
• Option C: Option C is incorrect; the 2022 AHA/ACC/HFSA guidelines do not recommend a fixed monthly monitoring schedule for 6 months regardless of dose changes; the interval is tied to pharmacodynamic events (initiation, dose increases) and then transitions to 6-monthly maintenance monitoring after the target dose is reached and tolerated; a fixed monthly schedule would over-monitor stable patients and under-specify the timing relative to dose changes.
• Option D: Option D is incorrect; delaying post-discharge laboratory monitoring to the 3-month clinic visit after in-hospital RAAS initiation is inadequate; the 1–2 week monitoring interval after initiation applies regardless of whether the drug was started in hospital or outpatient; early laboratory checks after discharge are particularly important given that the patient's volume status and renal hemodynamics will change substantially post-discharge from the inpatient environment.
• Option E: Option E is incorrect; the 2022 AHA/ACC/HFSA guidelines do recommend scheduled (not merely symptom-triggered) laboratory monitoring after RAAS blocker initiation; hyperkalemia and creatinine elevation are frequently asymptomatic until clinically significant — relying solely on patient-reported symptoms would miss the majority of early adverse renal and electrolyte events.

ANSWER: D

Rationale:

Option D is correct. This patient is an ideal candidate for transition from ACEi to sacubitril/valsartan. The 2022 AHA/ACC/HFSA guidelines give sacubitril/valsartan a Class I recommendation (Level of Evidence A) as the preferred RAAS-blocking agent for patients with HFrEF (LVEF ≤40%) who can tolerate it. "Can tolerate it" means: hemodynamically stable (SBP ≥90–100 mmHg), adequate renal function, acceptable potassium, and no contraindication (no history of ACEi- or ARNI-associated angioedema). This patient meets all criteria — her BP, renal function, and potassium are appropriate, and she has no angioedema history. Transitioning from ACEi to ARNI in eligible patients is a Class I guideline recommendation to further reduce mortality and morbidity beyond what ACEi therapy provides. The PARADIGM-HF evidence base establishes that sacubitril/valsartan reduces cardiovascular death, all-cause mortality, and HF hospitalization compared to enalapril — the agent she is currently receiving. The transition protocol is: stop enalapril today, wait 36 hours, then start sacubitril/valsartan 49/51 mg twice daily, titrating to 97/103 mg twice daily every 2–4 weeks as tolerated. Remaining on enalapril when the patient is ARNI-eligible leaves a demonstrated mortality benefit unrealized.

• Option A: Option A is incorrect; enalapril is not equivalent to sacubitril/valsartan for mortality reduction — PARADIGM-HF directly demonstrated superiority of sacubitril/valsartan over enalapril; the recommendation to transition ACEi-tolerant, ARNI-eligible patients is precisely because the two are not equivalent.
• Option B: Option B is incorrect; the mortality benefit of sacubitril/valsartan in PARADIGM-HF is attributable to the combination of neprilysin inhibition (sacubitril) and AT1 blockade (valsartan), not to the valsartan component alone; the PARADIGM-HF comparator was enalapril (an ACEi), not standalone valsartan; transitioning to valsartan alone does not replicate the ARNI benefit.
• Option C: Option C is incorrect; the 2022 AHA/ACC/HFSA guidelines do not require a maximum-dose ACEi trial before ARNI transition; the guideline recommendation is to transition ARNI-eligible patients from ACEi to sacubitril/valsartan when clinically appropriate; enalapril 10 mg twice daily was the dose used in PARADIGM-HF and represents adequate ACEi exposure; no mandatory uptitration documentation is required before ARNI transition.
• Option E: Option E is incorrect; the Class I recommendation for sacubitril/valsartan in the 2022 guidelines applies to symptomatic HFrEF patients (NYHA class II–IV) with LVEF ≤40% who can tolerate it; it is not restricted to NYHA class III–IV; PARADIGM-HF enrolled predominantly NYHA class II–III patients and demonstrated benefit across these classes; deferring ARNI transition until a patient develops class III symptoms would unnecessarily delay a mortality-reducing intervention. CLOSING NOTE: This question set covers the pharmacological mechanisms, clinical trial evidence, dosing and transition protocols, biomarker implications, and special population management for RAAS-blocking therapy in HFrEF — the core content of CHF-02. Facility with these concepts supports clinical decision-making across the full spectrum of HFrEF management, from initial drug selection through long-term monitoring and therapeutic optimization.